Affiliation: | a INSERM, U422, Unité de Neuroendocrinologie et Physiopathologie Neuronale, place de Verdun, 59045 Lille Cedex, France b Neuroscience Research institute, State University of New York at Old Westbury, Old Westbury, NY 11568, USA c Centre de Biologie Cellulaire, Laboratoire de Phylogénie moléculaire des Annélides, EA DRED 1027, Groupe de Neuroendocrinologie des Hirudinés, Université des Sciences et Technologies de Lille, 59650 Villeneuve d'Ascq, France d Laboratoire de Neuroendocrinologie du Developpement, Université des Sciences et Technologies de Lille, 59650 Villeneuve d'Ascq, France |
Abstract: | Nitric oxide (NO) is involved in neurohormonal secretion from median eminence neuroendocrine nerve terminals. We report that stimulation of NO release from median eminence fragments including vascular tissues occurs by μ3 receptor activation by morphine, or by cannabinoid type 1 receptor activation by anandamide. The released levels of NO are lower after anandamide than after morphine stimulation. These processes can be blocked by L-NAME, a specific nitric oxide synthase inhibitor, by naloxone for the morphine-stimulated NO release, or SR 141716A, a specific CB1 receptor inhibitor, for the anandamide-stimulated NO release. Furthermore, morphine and anandamide, by this NO dependent process, influences neurohormonal release from median eminence nerve terminals within 10 min. Via this NO dependent process, morphine stimulates both GnRH and CRF release, whereas anandamide selectively stimulates GnRH release. These observations together with previous data suggest that morphine and the anandamide-stimulated NO originates from the vascular endothelium of the portal plexus. These results indicate that endothelial cells of the median eminence may be involved in the release of neurohormones. |